|
注册号: Registration number: |
ChiCTR2200066325 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-07 23:20:47 |
|
注册时间: Date of Registration: |
2022-12-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
耳机材料刺激性及致敏性临床研究 |
|
Public title: |
Clinical study on irritation and sensitization of earphone materials |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
耳机材料刺激性及致敏性临床研究 |
|
Scientific title: |
Clinical study on irritation and sensitization of earphone materials |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赖迪辉 |
研究负责人: |
程少为 |
|
Applicant: |
Dihui Lai |
Study leader: |
Shaowei Cheng |
|
申请注册联系人电话: Applicant telephone: |
+86 189 1158 7612 |
研究负责人电话:
Study leader's |
+86 139 1199 6360 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
drlaidihui@163.com |
研究负责人电子邮件: Study leader's E-mail: |
13911996360@139.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区垂杨柳南街2号 |
研究负责人通讯地址: |
北京市朝阳区垂杨柳南街2号 |
|
Applicant address: |
2, Chuiyangliu South Street, Chaoyang District, Beijing |
Study leader's address: |
2, Chuiyangliu South Street, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京市垂杨柳医院 |
||
|
Applicant's institution: |
Beijing Chuiyangliu Hospital |
||
|
研究负责人所在单位: |
北京市垂杨柳医院 |
||
|
Affiliation of the Leader: |
Beijing Chuiyangliu Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
垂杨柳伦审[2022-010KY]号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京市垂杨柳医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of Beijing Chuiyangliu Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-07-08 00:00:00 | ||
|
伦理委员会联系人: |
李亚男 |
||
|
Contact Name of the ethic committee: |
Yanan Li |
||
|
伦理委员会联系地址: |
北京市朝阳区垂杨柳南街2号 |
||
|
Contact Address of the ethic committee: |
2, Chuiyangliu South Street, Chaoyang District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6770064 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京市垂杨柳医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing ChuiYangLiu Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区垂杨柳南街2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2, Chuiyangliu South Street, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
华为终端有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Huawei Device Co., LTD |
||||||||||||||||||||||
|
研究疾病: |
耳部皮肤疾病 |
||||||||||||||||||||||
|
Target disease: |
Ear skin disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
(1)查找耳机造成的外耳皮肤损害的原因及发生机制。 (2)寻找耳机原料中导致变应性接触性皮炎的过敏原或刺激性接触性皮炎的刺激物。 (3)收集耳机导致的皮肤健康问题,形成病例库。 (4)建立耳机相关的皮肤健康问题临床分析路径。 (5)筛选对皮肤没有损害(或损害小)的耳机化学涂料。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Search the causes and mechanisms of skin damage to the external ear caused by earphones. (2) Look for allergens or irritants that cause allergic contact dermatitis in earphone raw materials. (3) Collect skin health problems caused by earphones and establish a case bank. (4) Establish a clinical analysis path for earphone-related skin health problems. (5) Screen the headset chemical coating with no damage to the skin (or little damage). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
第一部分(临床病例研究): 1.不同意进行个人信息采集的; 2.无临床症状者。 第二部分(斑贴试验): 1.有速发型接触性反应史(如接触性荨麻疹)的患者; 2.有接触性变应原相关的全身性过敏反应史的患者; 3.孕妇和哺乳期妇女; 4.无行为控制能力或不能保证斑贴试验条件的患者; 5.正在使用糖皮质激素者,若系统应用相当泼尼松剂量 <= 每日0.4 mg/kg,通常影响较小,否则需等到药物停用2周以后;若糖皮质激素外用在斑贴测试部位,则需等到停药1周以后。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Part 1 (Clinical Case Study): 1. Disagree to collect personal information; 2. Those without clinical symptoms. Part 2 (Patch Test): 1. Patients with a history of immediate contact reactions (such as contact Hives); 2. Patients with a history of systemic allergic reactions related to contact allergens; 3. Pregnant and lactating women; 4. Patients who lack behavioral control ability or cannot guarantee patch test conditions; 5. For those who are currently using glucocorticoids, if the systematic application of prednisone dose is less than or equal to 0.4 mg/kg per day, the impact is usually small. Otherwise, it is necessary to wait until 2 weeks after the drug is discontinued; If glucocorticoids are applied externally to the patch test site, it is necessary to wait for one week after discontinuing the medication. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-01 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-12-05 00:00:00 至 To 2023-06-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机对照试验 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Non RCT |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |